Hodgkin Lymphoma-Like Posttransplant Lymphoproliferative Disorder (HL-Like PTLD) Simulates Monomorphic B-Cell PTLD Both Clinically and Pathologically

Sean D. Pitman(Loma Linda University Medical Center), Jun Wang(Third Affiliated Hospital of Zhengzhou University), Jesús G. Berdeja(Tennessee Oncology), Jeffrey D. Cao, Edward H. Rowsell, Craig W. Zuppan(Loma Linda University Medical Center), Lawrence M. Weiss(NeoGenomics (United States)), Qin Huang(People's Hospital of Xinjiang Uygur Autonomous Region)

The American Journal of Surgical Pathology

April 1, 2006

10.1097/00000478-200604000-00007

Cited by 61

Related Papers

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

|New England Journal of Medicine|2019|1.7k

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

|The Lancet|2021|1.7k

Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages

|Blood|2016|1.6k

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

|New England Journal of Medicine|2023|695

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683